Micronazole (Itraconazole)

Itraconazole is an azole antifungal used to treat invasive fungal infections.

• Invasive aspergillosis: effective therapy to eradicate Aspergillus species and improve survival.
• Candidemia and other serious Candida infections: clears bloodstream Candida and reduces organ involvement.
• Blastomycosis: treats systemic Blastomyces dermatitidis infection.
• Histoplasmosis: resolves disseminated Histoplasma capsulatum disease.
• Sporotrichosis: eliminates deep‑tissue Sporothrix schenckii infection.

• Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform responsible for converting lanosterol to ergosterol. By blocking this step, the drug disrupts ergosterol synthesis, compromising the integrity of the fungal cell membrane and leading to inhibited growth and eventual cell death. The inhibition is selective for fungal enzymes, resulting in minimal effect on human cholesterol synthesis at therapeutic concentrations.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Vomiting: occasional emesis.
• Diarrhea: loose stools.
• Abdominal pain: crampy discomfort.
• Headache: transient headache.
• Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury or failure.
• Congestive heart failure: worsening of cardiac function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Visual disturbances: blurred vision or photophobia.
• Anaphylaxis: acute allergic reaction.

Before using Micronazole, clinicians should consider several precautionary measures to ensure patient safety.

• Pregnancy: contraindicated in pregnancy (Category D); avoid unless benefits outweigh risks.
• Liver function: assess hepatic enzymes; use with caution in hepatic impairment.
• Cardiac function: monitor patients with existing heart failure; risk of worsening.
• Drug interactions: review concomitant medications that affect CYP3A4.
• Renal function: adjust dosing in severe renal impairment if applicable.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Itraconazole interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid)

• Rifampin: strong CYP3A4 inducer reduces itraconazole levels.
• Ketoconazole: additive hepatotoxicity risk.
• Statins (simvastatin, lovastatin): increased risk of rhabdomyolysis.
• Certain antiarrhythmics (e.g., quinidine): may cause arrhythmias.
• Oral contraceptives: decreased efficacy, risk of unintended pregnancy.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (verapamil, diltiazem): increased itraconazole concentrations.
• Antifungal azoles (fluconazole): potential additive toxicity.
• Proton pump inhibitors: may reduce absorption.
• HIV protease inhibitors (ritonavir): may increase itraconazole levels.
• Warfarin: enhanced anticoagulant effect, monitor INR.